Ondine Biomedical Inc.
OBIMF
$0.25
$0.0847.06%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.90M | 1.74M | 1.58M | 1.53M | 1.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.90M | 1.74M | 1.58M | 1.53M | 1.49M |
| Cost of Revenue | 742.00K | 641.00K | 540.80K | 532.70K | 531.10K |
| Gross Profit | 1.16M | 1.10M | 1.04M | 995.40K | 962.70K |
| SG&A Expenses | 7.03M | 7.50M | 8.01M | 7.97M | 8.03M |
| Depreciation & Amortization | 373.30K | 381.10K | 390.40K | 387.90K | 390.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.38M | 21.11M | 18.87M | 17.16M | 15.66M |
| Operating Income | -21.48M | -19.37M | -17.29M | -15.63M | -14.17M |
| Income Before Tax | -21.15M | -19.12M | -17.12M | -15.42M | -13.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.15 | -19.12 | -17.12 | -15.42 | -13.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.15M | -19.12M | -17.12M | -15.42M | -13.92M |
| EBIT | -21.48M | -19.37M | -17.29M | -15.63M | -14.17M |
| EBITDA | -21.14M | -19.04M | -16.99M | -15.41M | -14.02M |
| EPS Basic | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 1.86B | 1.68B | 1.49B | 1.29B | 1.10B |
| Average Diluted Shares Outstanding | 1.86B | 1.68B | 1.49B | 1.29B | 1.10B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |